Profile
| Role | Director |
|---|---|
| Notability | 20/100 |
Board memberships
- Inhibitor Therapeutics, Inc.
- Alaunos Therapeutics, Inc.
Updated Jul 17, 2026
Jerman Michael Allen has filed 2 SEC Form 4 filings across 2 companies in the last 90 days.
| Role | Director |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-24 | INTI | Inhibitor Therapeutics, Inc. | A — Grant or award | 50.0K | $0.00 | |
| 2026-05-01 | TCRT | Alaunos Therapeutics, Inc. | A — Grant or award | 6.0K | $2.59 | $16K |
| 2026-01-15 | TCRT | Alaunos Therapeutics, Inc. | A — Grant or award | 5.4K | $2.89 | $16K |
| 2025-11-27 | TCRT | Alaunos Therapeutics, Inc. | A — Grant or award | 4.2K | $3.16 | $13K |
| 2024-04-01 | INTI | Inhibitor Therapeutics, Inc. | A — Grant or award | 50.0K | $0.00 |
Jerman Michael Allen is a corporate insider — currently tracked as Director of Inhibitor Therapeutics, Inc. (INTI). InsiderAlpha tracks every SEC Form 4 filing in real time.
2 primary Form 4 filings in the last 90 days, covering 2 companies.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Jerman Michael Allen profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.